Cargando…
Robust Effect of Hepatic Arterial Infusion Chemotherapy and Radiation Therapy on Hepatocellular Carcinoma Arising from Fontan-associated Liver Disease
Fontan-associated liver disease (FALD) caused by long-term systemic venous congestion following the Fontan procedure may eventually lead to hepatocellular carcinoma (HCC). Treatment strategies for HCC due to FALD (FALD-HCC) remain unclear. We herein report a 35-year-old man with FALD-HCC that was we...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Society of Internal Medicine
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9107970/ https://www.ncbi.nlm.nih.gov/pubmed/34565776 http://dx.doi.org/10.2169/internalmedicine.8154-21 |
_version_ | 1784708601283084288 |
---|---|
author | Suzuki, Hiroyuki Niizeki, Takashi Shirono, Tomotake Koteda, Yusuke Kinjyo, Yoshinao Mizukami, Naohisa Koda, Makoto Ota, Satoshi Nakano, Masahito Okamura, Shusuke Iwamoto, Hideki Shimose, Shigeo Noda, Yu Kamachi, Naoki Kajiwara, Akira Suda, Kenji Akiba, Jun Yano, Hirohisa Kuromatsu, Ryoko Koga, Hironori Torimura, Takuji |
author_facet | Suzuki, Hiroyuki Niizeki, Takashi Shirono, Tomotake Koteda, Yusuke Kinjyo, Yoshinao Mizukami, Naohisa Koda, Makoto Ota, Satoshi Nakano, Masahito Okamura, Shusuke Iwamoto, Hideki Shimose, Shigeo Noda, Yu Kamachi, Naoki Kajiwara, Akira Suda, Kenji Akiba, Jun Yano, Hirohisa Kuromatsu, Ryoko Koga, Hironori Torimura, Takuji |
author_sort | Suzuki, Hiroyuki |
collection | PubMed |
description | Fontan-associated liver disease (FALD) caused by long-term systemic venous congestion following the Fontan procedure may eventually lead to hepatocellular carcinoma (HCC). Treatment strategies for HCC due to FALD (FALD-HCC) remain unclear. We herein report a 35-year-old man with FALD-HCC that was well controlled by 3 cycles of continuous infusion of 5-fluorouracil and low-dose cisplatin (low-dose FP therapy) combined with 60 Gy of radiation therapy. However, the patient ultimately died of extrahepatic metastases. A pathological autopsy revealed more than 90% necrosis in the primary HCC lesion. This case suggests that low-dose FP therapy might be effective in FALD-HCC. |
format | Online Article Text |
id | pubmed-9107970 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | The Japanese Society of Internal Medicine |
record_format | MEDLINE/PubMed |
spelling | pubmed-91079702022-05-27 Robust Effect of Hepatic Arterial Infusion Chemotherapy and Radiation Therapy on Hepatocellular Carcinoma Arising from Fontan-associated Liver Disease Suzuki, Hiroyuki Niizeki, Takashi Shirono, Tomotake Koteda, Yusuke Kinjyo, Yoshinao Mizukami, Naohisa Koda, Makoto Ota, Satoshi Nakano, Masahito Okamura, Shusuke Iwamoto, Hideki Shimose, Shigeo Noda, Yu Kamachi, Naoki Kajiwara, Akira Suda, Kenji Akiba, Jun Yano, Hirohisa Kuromatsu, Ryoko Koga, Hironori Torimura, Takuji Intern Med Case Report Fontan-associated liver disease (FALD) caused by long-term systemic venous congestion following the Fontan procedure may eventually lead to hepatocellular carcinoma (HCC). Treatment strategies for HCC due to FALD (FALD-HCC) remain unclear. We herein report a 35-year-old man with FALD-HCC that was well controlled by 3 cycles of continuous infusion of 5-fluorouracil and low-dose cisplatin (low-dose FP therapy) combined with 60 Gy of radiation therapy. However, the patient ultimately died of extrahepatic metastases. A pathological autopsy revealed more than 90% necrosis in the primary HCC lesion. This case suggests that low-dose FP therapy might be effective in FALD-HCC. The Japanese Society of Internal Medicine 2021-09-25 2022-04-15 /pmc/articles/PMC9107970/ /pubmed/34565776 http://dx.doi.org/10.2169/internalmedicine.8154-21 Text en Copyright © 2022 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Case Report Suzuki, Hiroyuki Niizeki, Takashi Shirono, Tomotake Koteda, Yusuke Kinjyo, Yoshinao Mizukami, Naohisa Koda, Makoto Ota, Satoshi Nakano, Masahito Okamura, Shusuke Iwamoto, Hideki Shimose, Shigeo Noda, Yu Kamachi, Naoki Kajiwara, Akira Suda, Kenji Akiba, Jun Yano, Hirohisa Kuromatsu, Ryoko Koga, Hironori Torimura, Takuji Robust Effect of Hepatic Arterial Infusion Chemotherapy and Radiation Therapy on Hepatocellular Carcinoma Arising from Fontan-associated Liver Disease |
title | Robust Effect of Hepatic Arterial Infusion Chemotherapy and Radiation Therapy on Hepatocellular Carcinoma Arising from Fontan-associated Liver Disease |
title_full | Robust Effect of Hepatic Arterial Infusion Chemotherapy and Radiation Therapy on Hepatocellular Carcinoma Arising from Fontan-associated Liver Disease |
title_fullStr | Robust Effect of Hepatic Arterial Infusion Chemotherapy and Radiation Therapy on Hepatocellular Carcinoma Arising from Fontan-associated Liver Disease |
title_full_unstemmed | Robust Effect of Hepatic Arterial Infusion Chemotherapy and Radiation Therapy on Hepatocellular Carcinoma Arising from Fontan-associated Liver Disease |
title_short | Robust Effect of Hepatic Arterial Infusion Chemotherapy and Radiation Therapy on Hepatocellular Carcinoma Arising from Fontan-associated Liver Disease |
title_sort | robust effect of hepatic arterial infusion chemotherapy and radiation therapy on hepatocellular carcinoma arising from fontan-associated liver disease |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9107970/ https://www.ncbi.nlm.nih.gov/pubmed/34565776 http://dx.doi.org/10.2169/internalmedicine.8154-21 |
work_keys_str_mv | AT suzukihiroyuki robusteffectofhepaticarterialinfusionchemotherapyandradiationtherapyonhepatocellularcarcinomaarisingfromfontanassociatedliverdisease AT niizekitakashi robusteffectofhepaticarterialinfusionchemotherapyandradiationtherapyonhepatocellularcarcinomaarisingfromfontanassociatedliverdisease AT shironotomotake robusteffectofhepaticarterialinfusionchemotherapyandradiationtherapyonhepatocellularcarcinomaarisingfromfontanassociatedliverdisease AT kotedayusuke robusteffectofhepaticarterialinfusionchemotherapyandradiationtherapyonhepatocellularcarcinomaarisingfromfontanassociatedliverdisease AT kinjyoyoshinao robusteffectofhepaticarterialinfusionchemotherapyandradiationtherapyonhepatocellularcarcinomaarisingfromfontanassociatedliverdisease AT mizukaminaohisa robusteffectofhepaticarterialinfusionchemotherapyandradiationtherapyonhepatocellularcarcinomaarisingfromfontanassociatedliverdisease AT kodamakoto robusteffectofhepaticarterialinfusionchemotherapyandradiationtherapyonhepatocellularcarcinomaarisingfromfontanassociatedliverdisease AT otasatoshi robusteffectofhepaticarterialinfusionchemotherapyandradiationtherapyonhepatocellularcarcinomaarisingfromfontanassociatedliverdisease AT nakanomasahito robusteffectofhepaticarterialinfusionchemotherapyandradiationtherapyonhepatocellularcarcinomaarisingfromfontanassociatedliverdisease AT okamurashusuke robusteffectofhepaticarterialinfusionchemotherapyandradiationtherapyonhepatocellularcarcinomaarisingfromfontanassociatedliverdisease AT iwamotohideki robusteffectofhepaticarterialinfusionchemotherapyandradiationtherapyonhepatocellularcarcinomaarisingfromfontanassociatedliverdisease AT shimoseshigeo robusteffectofhepaticarterialinfusionchemotherapyandradiationtherapyonhepatocellularcarcinomaarisingfromfontanassociatedliverdisease AT nodayu robusteffectofhepaticarterialinfusionchemotherapyandradiationtherapyonhepatocellularcarcinomaarisingfromfontanassociatedliverdisease AT kamachinaoki robusteffectofhepaticarterialinfusionchemotherapyandradiationtherapyonhepatocellularcarcinomaarisingfromfontanassociatedliverdisease AT kajiwaraakira robusteffectofhepaticarterialinfusionchemotherapyandradiationtherapyonhepatocellularcarcinomaarisingfromfontanassociatedliverdisease AT sudakenji robusteffectofhepaticarterialinfusionchemotherapyandradiationtherapyonhepatocellularcarcinomaarisingfromfontanassociatedliverdisease AT akibajun robusteffectofhepaticarterialinfusionchemotherapyandradiationtherapyonhepatocellularcarcinomaarisingfromfontanassociatedliverdisease AT yanohirohisa robusteffectofhepaticarterialinfusionchemotherapyandradiationtherapyonhepatocellularcarcinomaarisingfromfontanassociatedliverdisease AT kuromatsuryoko robusteffectofhepaticarterialinfusionchemotherapyandradiationtherapyonhepatocellularcarcinomaarisingfromfontanassociatedliverdisease AT kogahironori robusteffectofhepaticarterialinfusionchemotherapyandradiationtherapyonhepatocellularcarcinomaarisingfromfontanassociatedliverdisease AT torimuratakuji robusteffectofhepaticarterialinfusionchemotherapyandradiationtherapyonhepatocellularcarcinomaarisingfromfontanassociatedliverdisease |